Eladocagene exuparvovec
As of the edition of 20 October 2026, Eladocagene exuparvovec is a gene: marketed, first approved in 2022 (EU); US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Gene
- Brand name
- Kebilidi
- First approved
- 18 July 2022 (EU)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- PTC Therapeutics; 2 holders in all
US protection
US protection ends in 2036.
US protection ends in 2036, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by PTC Therapeutics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| PTC Therapeutics | Applicant | 2022 to now |